Urgent challenges in quantification and interpretation of brain grey matter atrophy in individual MS patients using MRI

Atrophy of the brain grey matter (GM) is an accepted and important feature of multiple sclerosis (MS). However, its accurate measurement is hampered by various technical, pathological and physiological factors. As a consequence, it is challenging to investigate the role of GM atrophy in the disease...

Descripción completa

Detalles Bibliográficos
Autores: Amiri, Houshang, de Sitter, Alexandra|||0000-0003-2579-9675, Bendfeldt, Kerstin, Battaglini, Marco|||0000-0002-9188-4408, Gandini Wheeler-Kingshott, Claudia A. M., Calabrese, Massimiliano|||0000-0002-3362-7403, Geurts, Jeroen J. G., Rocca, Maria A.|||0000-0003-2358-4320, Sastre-Garriga, Jaume|||0000-0002-1589-2254, Enzinger, Christian|||0000-0001-9764-7617, De Stefano, Nicola|||0000-0003-4930-7639, Filippi, Massimo|||0000-0002-5485-0479, Rovira, Álex, Barkhof, Frederik|||0000-0003-3543-3706, Vrenken, Hugo|||0000-0001-9106-1172
Tipo de recurso: artículo
Fecha de publicación:2018
País:España
Institución:Universitat Autònoma de Barcelona
Repositorio:Dipòsit Digital de Documents de la UAB
Idioma:inglés
OAI Identifier:oai:ddd.uab.cat:227943
Acceso en línea:https://ddd.uab.cat/record/227943
https://dx.doi.org/urn:doi:10.1016/j.nicl.2018.04.023
Access Level:acceso abierto
Palabra clave:BET, brain extraction tool
CNS, central nervous system
CTh, cortical thickness
DGM, deep grey matter
DTI, diffusion tensor imaging
FA, fractional anisotropy
GM, grey matter
MRI, magnetic resonance imaging
MS, multiple sclerosis
TE, echo time
TI, inversion time
TR, repetition time
VBM, voxel-based morphometry
WM, white matter
Multiple sclerosis
Brain atrophy
Grey matter
Magnetic resonance imaging
Descripción
Sumario:Atrophy of the brain grey matter (GM) is an accepted and important feature of multiple sclerosis (MS). However, its accurate measurement is hampered by various technical, pathological and physiological factors. As a consequence, it is challenging to investigate the role of GM atrophy in the disease process as well as the effect of treatments that aim to reduce neurodegeneration. In this paper we discuss the most important challenges currently hampering the measurement and interpretation of GM atrophy in MS. The focus is on measurements that are obtained in individual patients rather than on group analysis methods, because of their importance in clinical trials and ultimately in clinical care. We discuss the sources and possible solutions of the current challenges, and provide recommendations to achieve reliable measurement and interpretation of brain GM atrophy in MS.

Similares en LA Referencia